Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate.

Hema Kothari, Pranav Kumar, Neeloo Singh

Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India.

Journal Article: Protein Expression and Purification (impact factor: 1.56). 02/2006; 45(1):15-21. DOI: 10.1016/j.pep.2005.10.002

Abstract

Diseases produced by protozoan parasites are one of the main causes of morbidity and mortality around the world, affecting millions of people. Among these, leishmaniasis has become the second most common cause of death and the problem is further complicated by the expansion of parasite resistance to the conventional drugs. The high rate of therapeutic failure thus calls for new rational approaches to develop alternative drugs. Understanding resistance mechanisms may help identify new targets for drug development. So we present here the cloning, expression, purification, and antibody production of a gene implicated in imparting resistance to pentavalent antimony (SbV) in clinical isolates of kala azar with a view to gain insight into the novel mechanism of its drug resistance.

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

antibody production
 
cloning
 
common cause
 
drug resistance
 
gain insight
 
imparting resistance
 
kala azar
 
main causes
 
morbidity
 
new rational approaches
 
new targets
 
parasite resistance
 
pentavalent antimony
 
protozoan parasites
 
Understanding resistance mechanisms